Metpil-GV2 Tablet is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, resulting in a reduction of postprandial hyperglycemia. The combined action of these agents targets multiple pathophysiological defects in type 2 diabetes, providing comprehensive glycemic control. Metpil-GV2 is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve target blood glucose levels. It should be used under medical supervision with regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis risk associated with Metformin. Dose adjustments may be necessary based on patient response and tolerability. This combination therapy offers a convenient and effective option for optimizing diabetes management.